Sarcoidosis vasculitis and diffuse lung diseases
Published: 2013-09-01
Editorial
The 2nd AIR meeting – Working together to translate idiopathic pulmonary fibrosis research into practice
Abstract 121 | PDF Downloads 49Page 5
Section 1: Update on idiopathic pulmonary fibrosis: epidemiology, natural history, disease staging and pathogenesis
Epidemiology of idiopathic pulmonary fibrosis in Europe – an update
Abstract 362 | PDF Downloads 121Page 6-12
Classification, natural history and staging of idiopathic pulmonary fibrosis
Abstract 292 | PDF Downloads 85Page 13-20
Section 2: Update on idiopathic pulmonary fibrosis: pathophysiology and future perspectives
Inflammation and dysregulated fibroblast proliferation – new mechanisms?
Abstract 120 | PDF Downloads 64Page 21-26
Molecular biomarkers in idiopathic pulmonary fibrosis and disease severity
Abstract 137 | PDF Downloads 53Page 27-32
Section 3: Management of idiopathic pulmonary fibrosis and implications for clinical practice - A case study series
Management of idiopathic pulmonary fibrosis and pulmonary hypertension
Abstract 110 | PDF Downloads 61Page 33-36
Gastro-oesophageal reflux and idiopathic pulmonary fibrosis
Abstract 111 | PDF Downloads 69Page 37-39
Pirfenidone treatment in a patient with IPF and possible initial hypersensitivity pulmonitis
Abstract 153 | PDF Downloads 70Page 40-43
Treatment switching in idiopathic pulmonary fibrosis: from triple therapy to enrollment into a clinical investigational drug trial
Abstract 113 | PDF Downloads 73Page 44-47
Management of a patient with familial idiopathic pulmonary fibrosis
Abstract 106 | PDF Downloads 132Page 48-51
Long-term management of IPF with pirfenidone – a clinical case study with 5 years follow-up
Abstract 219 | PDF Downloads 72Page 52-62
Conclusions
The 2nd AIR meeting - the current context of European IPF research and management
Abstract 93 | PDF Downloads 55Page 63-64